Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JCP.0b013e3182a607ff | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fibromyalgia: do I tackle you with pharmacological treatments?
Pain Rep
February 2025
Pain Department, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, INSERM U987, Paris, France.
Pharmacological approaches are frequently proposed in fibromyalgia, based on different rationale. Some treatments are proposed to alleviate symptoms, mainly pain, fatigue, and sleep disorder. Other treatments are proposed according to pathophysiological mechanisms, especially central sensitization and abnormal pain modulation.
View Article and Find Full Text PDFPatterns of Medication for Opioid Use Disorder During Pregnancy, 7 Clinical Sites, MATernaL and Infant clinical NetworK (MAT-LINK), 2014-2021.
J Addict Med
December 2024
From the Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, GA (ELT, AND, KM, SMG, LG, DMM-D, SYK); Eagle Global Scientific, Atlanta, GA (ELT, AND); G2S Corporation, Shavano Park, Texas (AND); Department of Epidemiology, Emory University, Atlanta, GA (AND); Friends Research Institute, Baltimore, MD (MT); University of New Mexico Health Sciences Center, Albuquerque, NM (PMS, LL); University of Rochester, Rochester, NY (NSS, SC); University of South Florida, Tampa, FL (TW, JML); Boston Medical Center, Boston, MA (EMW, HS); University of Utah, Salt Lake City, UT (MS, JS); Center for Health Research, Kaiser Permanente Northwest, Portland, OR (MH, AD); and The Ohio State University, Columbus, OH (PDS, KR).
Article Synopsis
- The study analyzed medication patterns for opioid use disorder (MOUDs) during pregnancies among a cohort of 3,911 expectant mothers with opioid use disorder (OUD) from seven clinical sites.
- It found that over 90% of pregnancies involving methadone were among publicly insured individuals, and there was an increasing usage of buprenorphine with naloxone and naltrexone in recent years.
- The research highlighted that most prenatal care and MOUD documentation occurred within the same trimester, but discontinuity in MOUD treatments across trimesters still existed, indicating a need for improved access to care during pregnancy.
Stimulation of kappa opioid receptors in the nucleus accumbens promotes feeding behavior in mice: Acute restoration of feeding during anorexia induced by 5-fluorouracil.
Eur J Pharmacol
December 2024
Department of Pathophysiology and Therapeutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, Japan. Electronic address:
Article Synopsis
- Scientists studied how a type of receptor in the brain called kappa (κ) opioid receptors affects eating and sugar levels in the body.
- They found that a drug called nalfurafine increased how much food animals ate, but only when they weren't hungry.
- This study suggests that nalfurafine might help people with a loss of appetite caused by cancer treatment.
Factors Associated with Relapses in Alcohol and Substance Use Disorder.
Eurasian J Med
December 2023
Sakarya Training and Research Hospital, Sakarya, Turkey.
Alcohol and substance use disorder (ASUD) is a chronic condition featuring relapses and remissions. Due to their multifactorial nature, the causes of relapses in ASUD are not fully understood and it is important to update the information. Therefore, we aimed to provide an update on research examining factors associated with relapses, organized into sections.
View Article and Find Full Text PDFReconsidering the role of depression and common psychiatric disorders as partners in the type 2 diabetes epidemic.
World J Diabetes
June 2024
Diabetes Care Unit, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome 00168, Italy.
Common psychiatric disorders (CPDs) and depression contribute significantly to the global epidemic of type 2 diabetes (T2D). We postulated a possible pathophysiological mechanism that through Bridge-Symptoms present in depression and CPDs, promotes the establishment of emotional eating, activation of the reward system, onset of overweight and obesity and, ultimately the increased risk of developing T2D. The plausibility of the proposed pathophysiological mechanism is supported by the mechanism of action of drugs such as naltrexone-bupropion currently approved for the treatment of both obesity/overweight with T2D and as separate active pharmaceutical ingredients in drug addiction, but also from initial evidence that is emerging regarding glucagon-like peptide 1 receptor agonists that appear to be effective in the treatment of drug addiction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!